Purdue, Actavis Settle OxyContin Patent Battle

Law360, New York (April 26, 2013, 1:15 PM EDT) -- Purdue Pharma LP and Actavis Inc. announced Friday that they've agreed to end a New York patent infringement suit seeking to block Actavis' generic version of abuse-deterrent formulations of Purdue's multibillion-dollar drug OxyContin.

The settlement calls for Actavis to acknowledge that its generic version of OxyContin infringes Purdue patents. In exchange, Actavis will be granted a license to market a specified number of bottles of its generic OxyContin beginning in 2014, pending approval of the product from the U.S. Food and Drug Administration on its Abbreviated...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.